Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Dose-escalation protocols used in the Phase 2 trial began at sub-therapeutic doses and escalated over 8-16 weeks, which is believed to minimize gastrointestinal adverse events
Case reports and small case series have described both tolerability and adverse outcomes in IBD patients receiving GLP-1 agonists, highlighting the need for individualized assessment
Free Radic Res 2001
McGill and Jaeschke 2014) and to biomarkers that are amenable to measurement within biofluids that are easy to obtain in humans (e.g., blood and urine)
Fulda S, Galluzzi L, Kroemer G
US$ 24.07
US$ 25.51
US$ 20.35
